(February 17, 2022, 4:06 PM EST) -- SAN DIEGO — A clinical-stage biopharmaceutical company and certain of its senior executives are wrong in contending that the lead plaintiff in a securities class action has failed to properly plead that statements they made regarding the drugmaker’s development of a monoclonal therapy for the treatment of COVID-19 were actionable in violation of federal securities laws because the lead plaintiff has provided sufficient detailed allegations that the defendants lacked any factual basis for making the statements they did, the lead plaintiff argues in a Feb. 7 opposition brief filed in California federal court....